Pembrolizumab (Keytruda) Injection
Pembrolizumab targets PD-1 for advanced cancer immunotherapy like Hodgkin lymphoma. HTS 3002.15.00.11 covers this monoclonal antibody immunological product in pre-filled syringes for retail therapeutic use.
Import Duty Rates by Country of Origin
Alternative Classifications
This product could be classified differently depending on its characteristics or intended use.
If toxins or cultures rather than antibodies
Immunotoxins or microbial cultures classify under other immunological subheadings.
Not sure which classification is right?
Our AI classifier can analyze your specific product and recommend the correct HTS code with confidence.
Import Tips & Compliance
• Include BLA number and monoclonal sequence data in entry summary
• Monitor for counterfeit risks; use serialized packaging verification
Related Products under HTS 3002.15.00.11
Rituximab Monoclonal Antibody Injection
Rituximab is a genetically engineered chimeric monoclonal antibody targeting CD20 on B-cells, used for treating non-Hodgkin lymphoma and rheumatoid arthritis. It falls under HTS 3002.15.00.11 as an immunological product containing monoclonal antibodies, put up in measured doses for retail sale in pre-filled syringes or vials.
Trastuzumab (Herceptin) Infusion Vial
Trastuzumab is a humanized monoclonal antibody against HER2 protein, used in HER2-positive breast cancer therapy. Classified under HTS 3002.15.00.11 for its immunological role in targeted cancer treatment, supplied in measured dose vials for retail pharmacy sale.
Infliximab (Remicade) Lyophilized Powder
Infliximab is a chimeric monoclonal antibody against TNF-alpha for psoriasis and ulcerative colitis. HTS 3002.15.00.11 applies to this biotech-derived immunological product in measured retail doses for reconstitution.
Cetuximab (Erbitux) Infusion Kit
Cetuximab is a chimeric monoclonal antibody against EGFR for colorectal cancer. Under HTS 3002.15.00.11 for retail-measured doses regulating tumor immunology.
Denosumab (Prolia) Prefilled Syringe
Denosumab is a human monoclonal antibody inhibiting RANKL for osteoporosis. HTS 3002.15.00.11 applies to this immunological product in retail syringes.
Ranibizumab (Lucentis) Intravitreal Injection
Ranibizumab is a humanized monoclonal antibody fragment for wet AMD. Classified HTS 3002.15.00.11 as immunological VEGF inhibitor in measured doses.